Table 2. Epidemiological, clinical and virological characteristics of Angolan treatment naïve patients with primary DRM.
| Sample ID | Gender | CD4 (cells/mm3) | Age (years) | Subtype (PR/RT) | Geographic region | Mutations to NRTI | Mutations to NNRTI |
| ANG11 | F | 599 | 42 | F1 | North | M184V | K101E, G190A |
| ANG13 | M | 516 | 26 | CRF02_AG | Central | - | K103N |
| ANG14 | M | 401 | 43 | A/U/A | South | - | K103N |
| ANG25 | F | 561 | 20 | F1 | Central | M184V | K103N |
| ANG41 | F | 353 | 45 | H/A/H | Central | - | Y181C |
| ANG42 | M | 442 | 30 | C | South | M184V | Y181C |
| ANG49 | M | 525 | 31 | D | South | M184V | Y106M |
| ANG54 | F | 538 | 35 | C | South | M184V | K103N |
| ANG70 | M | 365 | 37 | H/U | North | M184V, T215F | K103N, M230L |
| ANG75 | F | 352 | 28 | U/H | Central | - | K103N |
| ANG80 | M | 355 | 39 | F1 | North | M184V | K103N |
| ANG100 | F | 502 | 19 | CRF02_AG | Central | T215F, M41L | - |
| ANG107 | M | 368 | 34 | U/H | Central | V75M, M184V | - |
| ANG111 | F | 494 | 29 | CRF18_cpx | Central | - | K103N |
NRTI, nucleoside reverse transcriptase inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors,